Quantitative Sensory Psychophysical Correlates of Pain in Pregnant Women With OUD (Q-PRONTO)
This is a prospective observational case-control study comparing quantitative sensory testing data preformed during the third trimester of pregnancy and within 24 hours postpartum in women on medication-assisted treatment for opioid use disorder (OUD) to a gestational age-controlled cohort of women who do not have OUD.
The primary goal is to measure elements of quantitative sensory testing including temperature pain threshold, temperature pain tolerance, and thermal and mechanical temporal summation for patients with opioid use disorder on medication-assisted treatment (MAT), and compare these results to gestational age matched controlled pregnant patients not on MAT.
調査の概要
詳細な説明
The objective of this study is to measure elements of quantitative sensory testing including temperature pain threshold, temperature pain tolerance, and thermal and mechanical temporal summation for patients with opioid use disorder on medication-assisted treatment (MAT), and compare these results to gestational age matched controlled pregnant patients not on MAT.
The hypothesis is that women requiring maintenance opioids during pregnancy will have a significant difference in pain sensitivity in the third trimester and immediately postpartum as compared to women who did not require maintenance opioids during pregnancy.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15213
- University of Pittsburgh Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
Subjects that will be included in the prospective cohort group:
- individuals at least 18 years of age
- at least 28 weeks gestation (third trimester)
- on medication-assisted treatment for opioid use disorder, including methadone or suboxone.
Patients who will be included in the control group:
- individuals at least 18 years of age
- at least 28 weeks gestation (third trimester)
- have not been on been on opioids in the past 12 months.
Exclusion Criteria:
- Those who are unable to participate in informed consent discussions,
- Unable to give informed consent for any reason,
- Not fluent in English (surveys are validated in English language)
- Unable to participate fully in all study procedures for any reason including sensory deficits, scar tissue, or infection at any QST sites.
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Prospective cohort group
This cohort will include pregnant patients with a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.
|
History of opioid use disorder.
|
|
Control group
This cohort will include pregnant patients without a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
QST Pain threshold
時間枠：Completed at a time point antepartum/ before delivery
|
Quantitative sensory testing is a pain sensitivity test in which the patient will tell the investigator the moment they first feel pain
|
Completed at a time point antepartum/ before delivery
|
|
QST Pain Tolerance
時間枠：Completed at a time point antepartum/ before delivery
|
Quantitative sensory testing is a pain sensitivity test in which the patient will tell the investigator the moment the sensation becomes uncomfortable.
|
Completed at a time point antepartum/ before delivery
|
|
QST Pain Threshold
時間枠：Completed within 24 hours postpartum/ after delivery
|
Quantitative sensory testing is a pain sensitivity test in which the patient will tell the investigator the moment they first feel pain
|
Completed within 24 hours postpartum/ after delivery
|
|
QST Pain Tolerance
時間枠：Completed within 24 hours postpartum/ after delivery
|
Quantitative sensory testing is a pain sensitivity test in which the patient will tell the investigator the moment the sensation becomes uncomfortable.
|
Completed within 24 hours postpartum/ after delivery
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Grace Lim, MD, MS、University of Pittsburgh
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
OUDの臨床試験
-
HealthPartners InstituteNational Institute on Drug Abuse (NIDA); Hennepin Healthcare Research Institute完了
-
University of Illinois at ChicagoNational Institute on Drug Abuse (NIDA)まだ募集していません
-
University of Colorado, DenverNational Institute on Drug Abuse (NIDA)完了
-
Center for Progressive Recovery, LLCNational Institute on Drug Abuse (NIDA); Yale University完了
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and Infectious Diseases...完了HIV感染症 | オピオイドの使用 | 薬物使用 | オピオイド使用障害アメリカ